Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-08-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于为全资子公司香港医学提供履约担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the provision of a performance guarantee for its wholly-owned subsidiary, Hong Kong Medical. It details the guarantee amount, the approval process by the board and shareholders, financial data of the subsidiary, and related opinions from the board, independent directors, and supervisors. The document is a formal disclosure about a corporate guarantee and related corporate governance procedures, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the guarantee and approval process. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate guarantee and related approvals that does not fit into more specific categories like capital/financing update or management information. The document length is 4084 characters, which is relatively short but contains detailed disclosure information rather than just a notice or certification.
2020-08-26 Chinese
中信证券股份有限公司关于公司与关联方开展委托研发的关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the review and opinion on related-party transactions involving Shenzhen BGI Genomics Co., Ltd. and its related parties for entrusted R&D activities. It includes comprehensive information about the related parties, transaction details, pricing policies, financial data, and approvals from the board, independent directors, and supervisory board. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal audit or review opinion on related-party transactions, which fits the category of an Audit Report / Information (AR). The length and detail confirm it is a full report, not just an announcement or regulatory filing. H1 2020
2020-08-26 Chinese
中信证券股份有限公司关于公司增加2020年度日常关联交易预计额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the increase in the 2020 annual expected amount of daily related-party transactions for Shenzhen BGI Genomics Co., Ltd. It includes extensive financial data, descriptions of related parties, transaction categories, pricing policies, and the necessity of these transactions. The content is regulatory and compliance-focused, related to ongoing connected transactions and their approval process, rather than a financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory filing about related-party transactions and their oversight. Therefore, it fits best under Regulatory Filings (RNS).
2020-08-26 Chinese
2020年半年度募集资金存放与实际使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a public offering by Shenzhen Huada Gene Co., Ltd. It includes specifics on the amount raised, allocation, usage, and compliance with regulatory requirements. The report references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and it provides detailed tables on fund usage, project investments, and financial management related to the raised capital. The document is titled as a "2020 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds" and contains substantive financial data and analysis for the half-year period ending June 30, 2020. This matches the characteristics of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and substantive financial data. It is not merely an announcement or certification, and it is longer than 5,000 characters, so it is not a report publication announcement or regulatory filing. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2020
2020-08-26 Chinese
董事、监事和高级管理人员所持公司股份及其变动管理制度
Director's Dealing Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 董事、监事和高级管理人员所持公司股份及其变动管理制度" which translates to "Shenzhen BGI Genomics Co., Ltd. Management System for Shares Held and Changes by Directors, Supervisors and Senior Management." The content details rules, principles, and procedures regarding the holding and trading of company shares by directors, supervisors, and senior management, including disclosure, lock-up periods, and compliance with securities laws. It is a governance-related internal policy document focused on insider shareholding and trading restrictions. There is no financial data, no audit information, no earnings or annual report content, no voting results, no capital changes, no legal proceedings, and no presentation or call transcript. The document is a governance and compliance policy related to insider shareholding and trading. Therefore, the most appropriate classification is "Director's Dealing (DIRS)" as it relates to the management and disclosure of directors' and senior management's shareholdings and transactions.
2020-08-26 Chinese
内部审计工作制度
Audit Report / Information Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 内部审计工作制度" which translates to "Internal Audit Work System of Shenzhen BGI Co., Ltd.". It is a detailed internal audit policy document outlining the principles, responsibilities, procedures, scope, and management of the company's internal audit function. It references regulatory frameworks and internal governance but does not contain financial statements, earnings data, or shareholder meeting materials. It is not an announcement or a brief summary but a comprehensive internal governance document related to audit practices. This fits best under the category of Audit Report / Information (AR), which includes applied accounting principles and internal audit results, excluding full annual reports. The document is 10,514 characters long, indicating it is a full policy document rather than a short announcement or certification. Therefore, the classification is AR with high confidence. FY 2020
2020-08-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.